23 completed, 12 recruiting, 8 terminated, 7 unknown. 56 Phase 2, 11 Phase 3, 2 Phase 1.
Follow Nephrosis: new trials by email Literature Review of Nephrosis trials Research Report on Nephrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| Effects of Meal Macronutrients on Postprandial Lipids High carb then high fat breakfast, High fat then high carb breakfast - Nephrotic Syndrome, Lipodystrophy | Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 100 | 2026-11-17 | 2026-11-12 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD) Obinutuzumab Injection, Predniso(lo)ne - Minimal Change Disease (MCD) | Phase 2 | Recruiting | Medical University Innsbruck | 48 | 2026-07-13 | 2026-08-17 |
| Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Everest Medicines (China) Co.,Ltd. | 45 | 2026-05-20 | 2026-08-05 |
| Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome Obinutuzumab - Nephrotic Syndrome，Idiopathic | Phase 2 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 10 | 2026-02-01 | 2026-01-26 |
| Dupilumab Therapy in Nephrotic Syndrome in Children Dupilumab, Placebo, Co-intervention of Prednisolone wean during randomised controlled phase - Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent | Phase 2 | Recruiting | National University Hospital, Singapore | 66 | 2025-11-27 | 2025-12-05 |
| SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome Dapagliflozin, Empagliflozin, Standard Therapy - Nephrotic Syndrome | Phase 2 / Phase 3 | Recruiting | Mansoura University | 75 | 2025-11-15 | 2026-06-09 |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis BAT4406F, Placebos - Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 192 | 2025-10-26 | 2026-04-03 |
| Atacicept in Multiple Glomerular Diseases Atacicept - pMN, IgAN | Phase 2 | Recruiting | Vera Therapeutics, Inc. | 250 | 2025-07-07 | 2026-06-26 |
| A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease frexalimab, brivekimig, rilzabrutinib - Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | Phase 2 | Recruiting | Sanofi | 84 | 2024-12-19 | 2026-11-12 |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases WAL0921, Placebo - Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Walden Biosciences | 96 | 2024-07-02 | 2026-08-03 |
| Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome single infusion of Rituximab, single infusion of Obinutuzumab - Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome | Phase 2 / Phase 3 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 88 | 2023-10-18 | 2026-11-06 |
| Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome Rituximab Biosimilar ABP 798, Daratumumab - Nephrotic Syndrome | Phase 2 | Unknown | Istituto Giannina Gaslini | 20 | 2023-03-01 | 2023-10-31 |
| Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome Rituximab, Mycophenolate Mofetil - Nephrotic Syndrome in Children | Phase 2 | Unknown | Children's Hospital of Chongqing Medical University | 46 | 2023-01-29 | 2024-04-19 |
| Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome ADX-629 - Nephrotic Syndrome | Phase 2 | Withdrawn | Aldeyra Therapeutics, Inc. | 2023-01-01 | 2024-04-17 | |
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases GFB-887 - Kidney Diseases, Glomerulosclerosis | Phase 2 | Terminated | Goldfinch Bio, Inc. | 31 | 2021-07-27 | 2022-11-15 |
| Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome Rituximab - Steroid-Sensitive Nephrotic Syndrome | Phase 2 | Completed | Children's Hospital of Fudan University | 44 | 2021-04-13 | 2023-07-11 |
Showing 20 of 56. Sign in to see all of them.
Nephrotic Syndrome (41) · Nephrosis, Lipoid (19) · Glomerulosclerosis, Focal Segmental (18) · Proteinuria (12) · Kidney Diseases (9) · Glomerulonephritis, Membranous (7) · Glomerulonephritis (6) · Glomerulonephritis, IGA (4) · Macular dystrophy, corneal type 1 (4) · Diabetic Nephropathies (3) · Nephritis (3) · Renal Insufficiency, Chronic (3) · Autoimmune Diseases (2) · Diabetes Mellitus (2) · Fibrosis (2)
Female Urogenital Diseases (56) · Female Urogenital Diseases and Pregnancy Complications (56) · Male Urogenital Diseases (56) · Urogenital Diseases (55) · Urologic Diseases (55) · Kidney Diseases (47) · Nephritis (25) · Glomerulonephritis (22) · Pathological Conditions, Signs and Symptoms (17) · Immune System Diseases (13) · Signs and Symptoms (13) · Urination Disorders (12) · Urological Manifestations (12) · Autoimmune Diseases (11)
Rituximab (9) · Prednisone (3) · Atorvastatin (2) · Cyclosporine (2) · Interleukin-2 (2) · Mycophenolic Acid (2) · Saline Solution (2) · obinutuzumab (2) · ofatumumab (2) · sparsentan (2) · 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide (1) · ADX-629 (1) · Abatacept (1) · Adalimumab (1) · Adrenocorticotropic Hormone (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8) · Istituto Giannina Gaslini (6) · Assistance Publique - Hôpitaux de Paris (3) · Goldfinch Bio, Inc. (2) · Mario Negri Institute for Pharmacological Research (2) · Travere Therapeutics, Inc. (2) · University Hospital, Limoges (2) · Aldeyra Therapeutics, Inc. (1) · Bellus Health Inc. - a GSK company (1) · Bio-Thera Solutions (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Nice (1) · Children's Hospital of Chongqing Medical University (1) · Children's Hospital of Fudan University (1) · Complexa, Inc. (1)
United States (26) · Italy (13) · France (8) · China (6) · Poland (4) · United Kingdom (4) · Germany (3) · Netherlands (3) · South Korea (3) · Spain (3) · Australia (2) · Belgium (2) · Canada (2) · Czechia (2) · Turkey (Türkiye) (2)
Gianmarco Ghiggeri, MD (4) · Anna Matyjek, MD, PhD (1) · Fanfan Hou, MD (1) · Feifei Xu, MD (1) · Fuming Lu, MD (1) · Gian Marco Ghiggeri, MD (1) · GianMarco Ghiggeri, MD (1) · Giuseppe L Remuzzi, M.D. (1) · Gloria L Vega, PhD (1)
PMID 39513526, PMID 38724717, PMID 40337980, PMID 35224732, PMID 17554116, PMID 25457107, PMID 26413873, PMID 28314744, PMID 30361325, PMID 31993781, PMID 32903623, PMID 32967877, PMID 33311560, PMID 33611671, PMID 33616641, PMID 34544820, PMID 34778952, PMID 34845071, PMID 34884411, PMID 35230699, PMID 36223961, PMID 36456193, PMID 36657027, PMID 36821613, PMID 37678236, PMID 37705972, PMID 38831932, PMID 39431468, PMID 39808779, PMID 39899371, PMID 40478760, PMID 40938675, PMID 41333097, PMID 41448676, PMID 41563842, PMID 41630898, PMID 42384439
2018 (2), 2025 (2), 2015 (1), 2017 (1), R21DK053611 (1)